Lilly seeks approval for Cymbalta in fibromyalgia
BOSTON, Aug 21 (Reuters) - Eli Lilly and Co. (LLY.N: Quote, Profile, Research, Stock Buzz) said on Tuesday it has filed for U.S. approval to sell its antidepressant Cymbalta as a treatment for the pain condition fibromyalgia.
The company said data shows that patients with and without depression who took Cymbalta showed greater reduction in pain than those who took a placebo.
Fibromyalgia is estimated to affect 2 percent to 4 percent of the U.S. population. It is characterized by widespread pain and fatigue, sometimes to a disabling degree.
Cymbalta is approved in the United States for the treatment of major depression, nerve pain associated with diabetes, and generalized anxiety.
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.
Have a correction to this article? Email the editors
economic plan
McCain offers his own economic plan